Printer Friendly

Eisai and BioArctic Neuroscience Enter Exclusive Licensing Agreement with Novel Antibody Treatment for Alzheimer's Disease.

Tokyo, Japan, Dec 4, 2007 - (JCN Newswire) - Eisai Co., Ltd. (TSE: 4523) and BioArctic Neuroscience AB (Headquarter: Stockholm, Sweden, CEO: Par Gellerfors) announced today that on December 3, they signed an exclusive licence agreement for BAN2401, a novel humanized monoclonal antibody, which is being developed as a next-generation therapeutic treatment for Alzheimer's disease. Under the terms of the agreement Eisai obtains the global rights to study, develop, manufacture and market BAN2401 for the treatment of Alzheimer's disease.

BAN2401 is the result of a strategic research alliance between Eisai and BioArctic initiated in 2005 to identify a potential immunotherapy for Alzheimer's disease. The research is based on the Arctic mutation of amyloid beta-peptide, discovered by Prof. Lannfelt at Uppsala University, which causes familial Alzheimer's disease.

BAN2401 is a humanized monoclonal antibody which selectively recognizes amyloid beta-peptide protofibrils, a form of soluble aggregate of amyloid beta-peptide believed to play a key role in the development of Alzheimer's disease. The antibody is currently in pre-clinical development and Eisai aims to develop a novel treatment for Alzheimer's disease using this antibody.

The licensing agreement for BAN2401, together with the gamma secretase modulator E2012 developed in-house by Eisai, allows the Company to pursue parallel approaches to developing next-generation treatments for Alzheimer's disease based on a small molecule compound and immunotherapy.

As a pioneer in Alzheimer's disease treatment, having discovered and developed Aricept(R)(donepezil hydrochloride), Eisai aims to accelerate the development of a new generation of treatments for Alzheimer's disease through in-house activities and alliances with outside organizations.

[1] BioArctic Neuroscience AB

BioArctic Neuroscience is a biopharmaceutical company established in 2003 with the aim of commercializing the research in Alzheimer's disease carried out by the internationally renowned researcher Prof. Lannfelt at Uppsala University.

[2]Pathogenesis of Alzheimer's disease and amyloid beta-peptide protofibrils

Accumulation of amyloid beta-peptide in the brain is believed to play a key role in the development of Alzheimer's disease. Pathologically, the accumulation is found as senile plaques containing aggregated insoluble amyloid beta-peptide fibrils. It is described that the toxic species causing Alzheimer's disease are the precursor forms of insoluble amyloid beta-peptide fibrils, the soluble amyloid beta-peptide aggregates including amyloid beta-peptide protofibrils.

3. Immunotherapy for Alzheimer's disease

As immunotherapies for Alzheimer's disease, there exist vaccine therapies that use amyloid beta-peptide to induce anti-amyloid beta-peptide immunoresponses, and antibody therapies that administrate monoclonal antibodies targeting amyloid beta-peptide. BAN2401 targets brain amyloid beta-peptide protofibrils by applying BioArctic Neuroscience's technology and it can efficiently eliminate amyloid beta-peptide species causing Alzheimer's disease.

4. Arctic mutation in amyloid beta-peptide

The Arctic mutation, which is one amino acid substitution in the amyloid beta-peptide peptide was discovered by Prof. Lannfelt at Uppsala University. This mutation causes familial Alzheimer's disease.

About Eisai Co., Ltd.

Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care company that discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Eisai employs more than 8,000 people worldwide. For more information, please visit http://www.eisai.co.jp.

Source: Eisai Co., Ltd.

Contact:
Corporate Communications Department
Eisai Co., Ltd.
Tel: +81-3-3817-5120


Japan Corporate News Network. All rights reserved.
COPYRIGHT 2007 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCN Newswires
Date:Dec 4, 2007
Words:539
Previous Article:Showa Denko K.K. (SDK) to Introduce Corporate Fellow System.
Next Article:Sharp Develops Industry's First Tuner Module Compatible with China Digital Television Terrestrial Broadcasting System Standard.
Topics:


Related Articles
AltaRex and United Therapeutics sign license agreement.
Lexicon Genetics, Bristol-Myers Squibb Establish Alliance.
New River agrees with Gallo Center to reduce opioid tolerance.
Eisai Announces Strategic Alliance With BioArctic Neuroscience To Develop Immunotherapy For Alzheimer's Disease.
Eisai Announces Inovelon(R) Receives Marketing Authorization Approval from European Commission.
Kissei and Eisai Sign a License Agreement to Develop and Commercialize Glufast(R), a Rapid-acting Insulin Secretagogue in 10 ASEAN Countries.
Kissei and Eisai Sign License Agreement to Develop and Commercialize Glufast(R), a Rapid-acting Insulin Secretagogue in China.
M's Science and Eisai Sign Option Agreement for Sigma Agonist SA4503.
Eisai Submits Application for AriceptR Oral Jelly Formulation in Japan.
HUMIRA(R) Subcutaneous Injection 40mg Syringe 0.8mL Now Available for the Treatment of Rheumatoid Arthritis.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters